You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 152 No. 4, APRIL 1992 TABLE OF CONTENTS
  Archives
  •  Online Features
  REVIEW ARTICLES
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (60)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Update on Rifampin Drug Interactions II

Shawn M. Borcherding, PharmD; Anne M. Baciewicz, PharmD; Timothy H. Self, PharmD

Arch Intern Med. 1992;152(4):711-716.


Abstract

Rifampin is a potent inducer of hepatic P450 oxidative enzymes. Clinically important drug interactions have been documented between rifampin and numerous other drugs, such as oral anticoagulants, oral contraceptives, cyclosporine, digitalis, and ketoconazole. New, potentially clinically significant rifampin drug interactions have been reported for haloperidol, several antiarrhythmics, fluconazole, diltiazem, and select benzodiazepines. Further research has been conducted for previously reported drug interactions with rifampin involving such drugs as glucocorticoids, cyclosporine, verapamil, and oral anticoagulants. Proper management of these interactions is essential to avoid therapeutic failures on initiating rifampin therapy and potential toxic reactions after discontinuing rifampin. New rifampin drug interactions will continue to be identified with future investigations.

(Arch Intern Med. 1992;152:711-716)



Author Affiliations

From the Department of Pharmacy Services, University Hospitals of Cleveland (Ohio) (Dr Baciewicz); and Department of Clinical Pharmacy, University of Tennessee, Memphis (Drs Borcherding and Self). Dr Borcherding is a University of Tennessee-Marion Merrell Dow Research Fellow.


Footnotes

Accepted for publication November 27, 1991.

Reprint requests to Department of Clinical Pharmacy, University of Tennessee, 26 S Dunlap St, Suite 200, Memphis, TN 38163 (Dr Self).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Novel Single Nucleotide Polymorphisms in the Promoter and Intron 1 of Human Pregnane X Receptor/NR1I2 and Their Association with CYP3A4 Expression
Lamba et al.
Drug Metab. Dispos. 2008;36:169-181.
ABSTRACT | FULL TEXT  

Rifampin and Rifabutin Drug Interactions: An Update
Finch et al.
Arch Intern Med 2002;162:985-992.
ABSTRACT | FULL TEXT  

Tuberculosis: 9. Treatment
Hershfield
CMAJ 1999;161:405-411.
FULL TEXT  

Update on Rifampin Drug Interactions, III
Strayhorn et al.
Arch Intern Med 1997;157:2453-2458.
ABSTRACT  

Cushing's Syndrome
Orth
NEJM 1995;332:791-803.
FULL TEXT  

Two Controlled Trials of Rifabutin Prophylaxis against Mycobacterium avium Complex Infection in AIDS
Nightingale et al.
NEJM 1993;329:828-833.
ABSTRACT | FULL TEXT  

Significance of Drug Interactions With Rifampin in Pneumocystis carinii Pneumonia Prophylaxis
Jorde et al.
Arch Intern Med 1992;152:2348-2348.
ABSTRACT  

Significance of Drug Interactions With Rifampin in Pneumocystis carinii Pneumonia Prophylaxis-Reply
Borcherding and Self
Arch Intern Med 1992;152:2348-2348.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1992 American Medical Association. All Rights Reserved.